Spry2 has been characterized as a negative regulator of the extracellular-regulated kinase (ERK) pathway. In this study we analysed whether epigenetic alterations of hSpry2 promoter occur in human lymphoid/hematopoietic malignancies. Our results revealed that hSpry2 promoter was hypermethylated in the HT cell line derived from a B-cell diffuse lymphoma, which correlated with decreased hSpry2 expression. We detected deregulation of the ERK pathway in these cells, but not in other blood cell lines expressing hSpry2. In addition, the ectopic overexpression of hSpry2 in HT cells drastically reduced the activation of ERK upon phorbol 12-myristate-13-acetate stimulation. Nude mice inoculated with HT mock cells developed tumors seven times larger than those from HT-hSpry2-transfected cells. We found hypermethylation of hSpry2 promoter in 37% (26 cases out of 71) of primary tumors from patients with B-cell diffuse lymphoma but none in normal B lymphocytes from 37 healthy individuals. Finally, we detected that hSpry2 promoter hypermethylation was associated with a significant decrease in the 5-year survival rate. These data suggest that hSpry2 could be important in lymphoid malignancies.
Spry2 has been characterized as a negative regulator of the extracellular-regulated kinase (ERK) pathway. In this study we analysed whether epigenetic alterations of hSpry2 promoter occur in human lymphoid/hematopoietic malignancies. Our results revealed that hSpry2 promoter was hypermethylated in the HT cell line derived from a B-cell diffuse lymphoma, which correlated with decreased hSpry2 expression. We detected deregulation of the ERK pathway in these cells, but not in other blood cell lines expressing hSpry2. In addition, the ectopic overexpression of hSpry2 in HT cells drastically reduced the activation of ERK upon phorbol 12-myristate-13-acetate stimulation. Nude mice inoculated with HT mock cells developed tumors seven times larger than those from HT-hSpry2-transfected cells. We found hypermethylation of hSpry2 promoter in 37% (26 cases out of 71) of primary tumors from patients with B-cell diffuse lymphoma but none in normal B lymphocytes from 37 healthy individuals. Finally, we detected that hSpry2 promoter hypermethylation was associated with a significant decrease in the 5-year survival rate. These data suggest that hSpry2 could be important in lymphoid malignancies. Oncogene (2008) 27, 4969-4972; doi:10.1038 /onc.2008 published online 21 April 2008 Keywords: hSpry2; epigenetic; lymphomas; B cells; suppressor gene Human Spry and Spred are two families of proteins that share a common domain and repress the receptor tyrosine kinase-extracellular-regulated kinase (ERK) pathway (for two recent reviews see Bundschu et al., 2007 and Cabrita and Christofori, 2008) . Forced expression of Spry2 inhibits fibroblast growth factor (FGF) and vascular endothelial growth factor, but not epidermal growth factor-induced ERK activation (Cabrita and Christofori, 2008) . As the ERK pathway is important in tumorigenic processes, it has been suggested that some members of the Spry or Spred families of proteins could act as tumor suppressors because of their capacity to block ERK activation (reviewed in Lo et al., 2006; Mason et al., 2006) . Recent studies have indicated a diminished expression of some of these genes in breast, prostate and hepatocellular carcinomas (reviewed in Lo et al., 2006; Mason et al., 2006; Bundschu et al., 2007) . In a few cases, molecular mechanisms underlying this downregulation have been described, including gene promoter methylation (McKie et al., 2005; Wang et al., 2006) , which ultimately disrupt several signaling pathways. Although the ERK pathway participates in the generation of mitogenic responses in essentially all hematologic malignancies (Platanias, 2003) , we are not aware of any data suggesting that the Spry family is involved in the development of lymphoid/hematopoietic tumors. This study was carried out to ascertain the epigenetic status of the hSpry2 gene in blood malignancies, and to explore its relevance in hematological carcinogenesis.
The criteria for assessing the presence of a cytosine phosphate-guanosine (CpG) island in the hSpry2 promoter have been described previously (GardinerGarden and Frommer, 1987) . Accordingly, we proposed that a CpG island is located between -290 and þ 150 bp from the transcription start site of the hSpry2 gene ( Figure 1a) .
To identify epigenetic alterations of the hSpry2 promoter, 16 established human cell lines derived from different lymphoid/hematopoietic tumors were analysed by methylation-specific polymerase chain reaction (MSP; Supplementary Figures S1 and S2), and we found that hSpry2 promoter was only methylated in the HT cell line, which is derived from a B-cell diffuse lymphoma. This was confirmed by bisulfite genomic sequencing, showing that the CpG island of the hSpry2 promoter was specifically methylated in this cell line ( Figure 1a) . We next examined whether the described hSpry2 hypermethylation detected in the HT cells was associated with transcriptional silencing of hSpry2. Expression analysis of the hSpry2 gene by reverse transcription (RT)-PCR showed that most hSpry2 mRNA was lost in the HT cell line, but that it could be reversed if the cells were treated with the DNA demethylating agent 5 0 -aza-2 0 -deoxycytidine (5 0 -aza-dC) (Egger et al., 2004; Figure 1b ; Supplementary Figures S3a and b) . In addition, we analysed the protein levels of hSpry2, and found that its expression was also reduced in the HT cell line but could be restored by treatment with 5 0 -aza-dC ( Figure 1b ; Supplementary Figure S3a ). To elucidate the repression mechanism of hSpry2 transcription, we performed a chromatin immunoprecipitation (ChIP) assay by testing the presence of methyl- (Esteller et al., 2002) , the detection of O-6-methylguanine DNA methyltransferase (MGMT) was performed using specific primers. As a loading control, the detection of b-actin was performed using specific primers (RT-PCR) or antibodies (western blot, from Sigma). (c) The ChIP assays of HT cells were performed as previously described (Lopez-Serra et al., 2006), using antibodies anti-methyl-CpG-binding domain (MBD, 1-3) and antiMeCP 2 from Abcam (Cambridge, UK) and protein A-agarose from Roche Molecular Biochemicals (Mannheim, Germany). The results show DNA amplification corresponding to the hSpry2 promoter with the input fraction immunoprecipitated (Bound fraction) only with anti-MeCP2. Also illustrated is the control DNA amplification of the same hSpry2 promoter region but without immunoprecipitation (Input fraction). In all cases (b, c) each figure is from a representative experiment that was repeated three times with similar results. In all panels, the sequence and exact position of the primers used can be found in Supplementary Figures S2. hSpry2 in B-cell lymphomas A Sánchez et al MBD protein (MeCP2, MBD1, MBD2 and MBD3). The results suggest that the MBD protein MeCP 2 is present on the hSpry2 promoter (Figure 1c ), which could mediate hSpry2 silencing. Spry2 proteins can inhibit the activation of ERK (Mason et al., 2006; Cabrita and Christofori, 2008) . We therefore tested whether the absence of hSpry2 in the HT cells affected the ERK pathway. We measured the time course of ERK activation in HT (alone or stably transfected with pECFP-hSpry2 wt, HT-pECFP-hSpry2 cells, or with the empty vector, HT-pECFP-mock cells), REH and HelR cells after treatment with phorbol 12-myristate-13-acetate (PMA), a classical stimulus for the Ras-GRP1/Ras/Raf/MEK/ERK signaling pathway in hematopoietic cells (Ebinu et al., 1998 ). We found that the level of ERK activation elicited in HT cells was higher and more persistent than in REH or HelR cells (Supplementary Figure S3c) ; these results are consistent with the expression of hSpry2 in REH and HelR cells, and its absence from the HT cell line (Supplementary Figure S3a) . In addition, the ectopic overexpression of hSpry2 in HT cells drastically reduced the activation of ERK (p-ERK1/p-ERK2) upon PMA stimulation (Figure 2a) . In view of these results, we examined the putative role of hSpry2 as a tumor suppressor in the HT cell line. To ascertain tumorogenicity in nude mice tumor assays, we used the above HT-pECFP-hSpry2 and HT-pECFP-mock cell lines. In agreement with previous findings from the hypermethylation of hSpry2 gene and deregulation of ERK activity, nude mice Figure 2 Biological significance of the hypermethylation of hSpry2 gene. (a) Full-length cDNA of hSpry2 subcloned into pECFP-C1 was obtained previously (Martı´nez et al., 2007) . HT cells were stably transfected using Gene-Pulser from Bio-Rad (Hercules, CA, USA) with 4 mg of pECFP-hSpry2 wt and the empty vector (pECFP-C1) to generate, respectively, the cell lines HT-pECFP-hSpry2 and HT-pECFP-mock. After transfection the cell lines were selected by geneticin (750 mg/ml) from Invitrogen (Carlsbad, CA, USA) for 3 weeks, and finally a secondary selection was carried out by cell sorting of cyan fluorescence using MoFlo High-Performance Cell Sorter from Becton Dickinson (Sparks, MD, USA). HT-pECFP-hSpry2 cells (overexpressing CFP-hSpry2) and HT-pECFP-mock cells (overexpressing CFP alone) were stimulated with phorbol 12-myristate-13-acetate (PMA) 500 nM from Sigma for the indicated times. Cells were then lysed under appropriate conditions (Martı´nez et al., 2007) and equal amounts of proteins were analysed by western blot. The levels of CFP-hSrpy2, CFP alone and phosphorylation of extracellular-regulated kinase (ERK, p42 and p44 proteins) were assessed using specific anti-green fluorescent protein (GFP), anti-phospho-ERK and anti-ERK antibodies from Cell Signaling (Beverly, MA, USA). The figure shown is from a representative experiment that was repeated three times with similar results. (b) Female athymic nude mice nu/nu (6-week old; Harlam Sprague-Dawley, Indianapolis, IN, USA), housed under specific pathogen-free conditions (Institutional Animal Welfare Committee Agreement), were used for HT tumor xenografts. Ten million cells in a total volume of 200 ml of phosphate-buffered saline (PBS) were injected subcutaneously into the flanks of each of six animal specimens. The right flank was used to inoculate HT-pEFCP-hSpry2 cells (HT-Spry2) and the left for HT-pECFP-mock control cells (HT-mock). The figure shows the results 60 days after injection. Animals were killed at 60 days. Tumors were then excised and measured (mass in mg, size in mm); *Po0.01. This HT tumor xenografts assay was done only one time. (c) We ascertained 71 unrelated individuals affected by B-cell diffuse lymphoma. Tumor samples were obtained from each patient, after they had given their informed consent, and the corresponding genomic DNA was isolated as previously described (Fraga et al., 2004) . The figure shows the methylation-specific polymerase chain reaction (MSP) analysis of all primary tumor samples from 71 B-cell diffuse lymphoma patients tested using this approach and confirmed by bisulfite genomic sequencing. Positive samples for methylation and bisulfite genomic sequencing are highlighted in red. Positive and negative controls for the MSP assay are indicated as in-vitro methylated DNA (IVD), and normal lymphocytes (NL), respectively. The negative control for PCR is denoted as H 2 O. Furthermore, B-cell diffuse lymphoma diagnosis was based on histopathology, immunophenotypic analysis of cell surface markers (CD10, CD19, CD20, CD22, CD79a, CD3, CD5, CD43, CD45RO, CD15, CD30 and CD45) and immunogenotypic analysis of immunoglobulin gene rearrangement, performed with the use of a JH probe on HindIII, EcoRI and BamHI digests and a Jk probe on BamHI digests. (d) Association between hSpry2 hypermethylation and poor outcome in lymphomas. hSpry2 hypermethylation is a marker of shorter 5-year overall survival in B-cell diffuse lymphoma patients. Contingency tables were analysed by Fisher's exact test. Five-year survival curves were estimated by the Kaplan-Meier method and were compared using the log-rank test. All statistical analyses were performed with SPSS version 10.1 (SPSS Inc, Chicago, IL, USA).
hSpry2 in B-cell lymphomas A Sánchez et al inoculated with HT-pECFP-mock cells developed tumors on their flanks that were seven times larger than those elicited by HT-pEFCP-hSpry2 cells ( Figure 2b ). Next, we investigated whether epigenetic alterations of hSpry2 promoter also occurred in human B-cell diffuse lymphomas. MSP analyses and bisulfite genomic sequencing of selected cases from 71 primary tumor samples from B-cell diffuse lymphoma patients (Figure 2c) showed that hSpry2 promoter was hypermethylated in 37% of cases (26 out of 71), whereas in normal B cells (from 37 healthy individuals) this promoter was without epigenetic alterations (Po0.001; Supplementary Figure S4a) . We also analysed whether other human lymphoid/hematopoietic malignancies contained epigenetic alterations of hSpry2 gene. We therefore found hypermethylation of hSpry2 promoter in 10 out of 13 Burkitt's lymphomas, and in one out of 14 samples of acute myeloid leukemia ( Supplementary  Figures S4b and c) . We then sought to establish whether there was a relationship between the hypermethylation status of the hSpry2 gene and the clinical outcome of B-cell diffuse lymphoma patients. Clinical information was available for 55 B-cell diffuse lymphoma patients of the initial 71 patients, and hSpry2 hypermethylation was observed in 36% (20 out of 55) of them. In these lymphomas, hSpry2 hypermethylation was independent of the lactate dehydrogenase level and clinical stage of the patients. In addition, the presence of hSpry2 promoter hypermethylation was significantly associated with a lower 5-year survival rate (Kaplan-Meier, P ¼ 0.0218; Figure 2d ). Thus, hSpry2 CpG island hypermethylation is a likely predictor of poor outcome in B-cell diffuse lymphoma patients.
These results are the first evidence that hSpry2 might be involved in lymphoid malignancies, and suggest that silencing of hSpry2 gene could be another barrier that lymphoid cells have to cross on their way to malignant transformation. Further characterization of the upstream regulatory signals for ERK, like that mediated by the Spry proteins, may provide more specific targets for translational approaches, including development of new DNA demethylating agents (Egger et al., 2004) that are able to reactivate hypermethylated negative-regulatory genes of the ERK pathway (such as hSpry2).
